Τίτλος:
Treatment of myelodysplastic syndromes with human granulocytic‐macrophage colony stimulating factor (GM‐CSF) or GM‐CSF combined with low‐dose cytosine arabinoside
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Abstract: In a phase II study, 21 patients with MDS (RAEB, RAEBt, CMML and RA and RAS with severe cytopenia) were randomized to be treated with 3 courses of GM‐CSF (3 μg/kg/day s.c.) alone (11 patients) or in combination with AraC (20 mg/m2/d s.c.) (10 patients) for 14‐d periods, interrupted by 14‐d rest periods. Eight patients discontinued the treatment. In the GM‐CSF group a marked increase in WBC and neutrophil counts during each course of treatment administration were seen in most patients. Platelet counts decreased in 14 of 24 courses of treatment in the GM‐CSF plus AraC group but in none of the GM‐CSF group. Although the changes in the circulating blood cells were transient and the counts tended to return to the pretreatment levels during the rest periods, some more durable effects were seen. In 3/6 patients of the GM‐CSF group who completed the designed treatment, both WBC and neutrophils remained elevated above the pretreatment levels throughout the 3‐month period of treatment, while in one of them thrombocytopenia improved considerably. In the GM‐CSF plus AraC group, 4 out of the 7 patients who completed the treatment showed an improvement of neutropenia as well as anaemia. In these 4 patients the BM percentage of blasts was also decreased. In conclusion, the results of this study indicate that GM‐CSF given intermittently improves leukopenia in some patients with MDS. In addition, the administration of GM‐CSF seems to prevent granulocytopenia of concurrent AraC treatment and may be of benefit in the treatment of these diseases. © Munksgaard 1992
Συγγραφείς:
Economopoulos, T.
Papageorgiou, E.
Stathakis, N.
Asprou, N.
Karmas, P.
Dervenoulas, J.
Bouronikou, H.
Chalevelakis, G.
Raptis, S.
Περιοδικό:
European Journal of Haematology
Λέξεις-κλειδιά:
cytarabine; granulocyte macrophage colony stimulating factor; cytarabine; granulocyte macrophage colony stimulating factor; shering plough, adult; aplastic anemia; article; chronic myelomonocytic leukemia; clinical article; human; influenza; myelodysplastic syndrome; skin disease; subcutaneous drug administration; aged; anemia; Article; bleeding; bone pain; chronic myelomonocytic leukemia; controlled study; drug efficacy; drug safety; drug tolerability; female; fever; leukocyte count; low drug dose; male; middle aged; monocyte count; neutropenia; neutrophil; neutrophil count; phase 2 clinical trial; platelet count; priority journal; randomized controlled trial; rash; refractory anemia with excess blasts; refractory anemia with excess blasts in transformation; refractory anemia with ringed sideroblasts; skin manifestation; thrombocytopenia; treatment duration; very elderly, Aged; Blood Cell Count; Cytarabine; Drug Therapy, Combination; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Human; Male; Middle Age; Myelodysplastic Syndromes
DOI:
10.1111/j.1600-0609.1992.tb00918.x
